Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
Price:
7.22
HKD
1.12%
Market Cap:
HK$5.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
|
CN |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
CA |
|
Vitesco Technologies Group AG
OTC:VTSCF
|
DE |
|
ALK-Abello A/S
F:4AJ0
|
DK |
|
A
|
AMCON Distributing Co
AMEX:DIT
|
US |
|
Y
|
Yijia Group Corp
OTC:YJGJ
|
HK |
|
H
|
Holding Company ADMIE IPTO SA
ATHEX:ADMIE
|
GR |
|
Signaux Girod SA
PAR:ALGIR
|
FR |
|
T
|
TimkenSteel Corp
NYSE:MTUS
|
US |
|
N
|
Nitin Spinners Ltd
NSE:NITINSPIN
|
IN |
|
J
|
JOST Werke AG
XETRA:JST
|
DE |
|
CENIT AG
XETRA:CSH
|
DE |
|
Mansi Finance (Chennai) Ltd
BSE:511758
|
IN |
|
Copperleaf Technologies Inc
TSX:CPLF
|
CA |
Multiples-Based Value
The
Multiples-Based Value for
Jacobio Pharmaceuticals Group Co Ltd (1167)
under the Base Case is
hidden
HKD.
Compared with the current market price of 7.22 HKD, the stock appears
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Jacobio Pharmaceuticals Group Co Ltd Multiples-Based Value
LOCKED
Multiples Across Competitors
Competitors Multiples
Jacobio Pharmaceuticals Group Co Ltd Competitors
Jacobio Pharmaceuticals Group Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Jacobio Pharmaceuticals Group Co Ltd
HKEX:1167
|
5.7B HKD | 93.6 | -34.3 | -22.3 | -22.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
367.6B USD | 6 | 87.8 | 14.6 | 20.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.2B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.5B USD | 5.9 | 20.3 | 12.7 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 9.2 | 28 | 21 | 22 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.2B EUR | 11.9 | 38.2 | 41.3 | 42.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 2.9 | 32.2 | 10.9 | 13.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
